We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Prostate Cancer Model Collection Will Advance the Development of New Treatments

Rectangle Image
News

Prostate Cancer Model Collection Will Advance the Development of New Treatments

Histological slide (H & E stain at x300) showing prostate cancer. On the right is a somewhat normal Gleason Value of 3 (out of 5) with moderately differentiated cancer. On the left is less normal tissue with a Gleason Value of 4 (out of 5) that is highly undifferentiated. Credit: Otis Brawley
Read time:
 

Researchers at Monash University have established one of the world’s largest collections of living tumours from prostate cancer patients, accelerating the testing of new treatments for prostate cancer and leading to faster patient benefit.

One of the most common cancers, prostate cancer is also one of the most difficult to study in the laboratory, with the frequently used models derived more than 40 years ago.  With the establishment of the Melbourne Urological Research Alliance (MURAL), hundreds of Victorian men have generously donated samples of their cancer tissue, enabling the team to study a greater diversity of live tumours and test the efficacy of a larger variety of therapies for their ability to stop tumour growth.

The PDX collection (patient-derived xenografts), developed by a multidisciplinary consortium and led by Professor Gail Risbridger and Associate Professor Renea Taylor at the Monash Biomedicine Discovery Institute (BDI), now comprises 59 tumours, collected from 30 patients between 2012 - 2020 and is now one of the largest collections of prostate cancer models in the world.

Full characterisation of the PDX collection is published in Nature Communications.

MURAL PDXs are an enduring resource of new cancer models that can be shared with other academic investigators or pharmaceutical companies.  The patients and their families are directly embedded in this venture, including the EJ Whitten Foundation who have been pivotal over the last 10 years in providing over $1M in donations enabling this resource to be developed and the program to come to the forefront of the international field.

“This project begins and ends with patients like EJ Whitten. We take patient tissue – do testing in the laboratory – and the discoveries then advance treatment for patients,” said Professor Risbridger. “Our new models of prostate cancer have attracted interest from scientists and the pharmaceutical industry worldwide.”

Ted Whitten, Executive Director and Founder of the E.J.Whitten Foundation congratulates the Monash University Biomedicine Discovery Institute on its recent findings in regards to Prostate Cancer research. “We believe that Monash University is a leader of Prostate Cancer Research and we have been delighted to have been able to financially support many of their important programs over the past ten years.”

Dr Mitchell Lawrence, also from Monash BDI and a senior author, says: “This resource provides an opportunity to link the molecular changes in prostate cancer to pathology, grow organoids and test functional responses to therapies, which have rarely been applied to prostate cancer given the lack of suitable models.”

Reference: Risbridger GP, Clark AK, Porter LH, et al. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat Commun. 2021;12(1):5049. doi: 10.1038/s41467-021-25175-5

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement